RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Asian markets are a world unto themselves. For example, Lundbeck's Lexapro, which is about to go off-patent next year in the US, was just approved for the first time in Japan earlier this year. These countries require trials with their own populations, and larger companies often outlicense those rights and headaches. Cortex and Samyang appear to have agreed that Samyang will (my guess, I haven't seen the MOU, obviously) have some priority in negotiations for these compounds, and would have a shot at widening their Asian territory. But there is no money changing hands on this, and no binding commitment on either side, so far as I can tell.

Anyways--this expression of interest vis-a-vis these Asian territories should not have any negative effect on any future negotiations for North America/Europe. The full range of clinical studies will be required in Asia, and there is a huge gap between this MOU and the start of any such testing. I don't think Samyang's expression of interest is going to have any impact on large companies--but it is a reminder to Servier that they do not necessarily have a monopoly on the Ampakine franchise. Which is a good thing.

Re: Neurolixis
Mark Varney and Newman-Tancredi are longtime friends, and Varney is providing very limited assistance to N-T in setting up this company. It has nothing to do with Ampakines, there is no transfer of IP or management, and hardly any time. It's not material to Cortex.

NeuroInvestment